A cross-disciplinary view of current and emerging COVID-19 developments.

Autor:	Bennett CM; Institute for Health Transformation, Deakin University, Melbourne, Victoria, Australia; catherine.bennett@deakin.edu.au., Riley B; ASHM Health, formerly known as Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Sydney, NSW, Australia., Morpeth S; Department of Microbiology and Infectious Diseases, Middlemore Hospital, Te Whatu Ora Counties Manukau, Auckland, New Zealand; Faculty of Medical and Health Sciences, University of Auckland, New Zealand., Lee WS; Department of Microbiology and Immunology, University of Melbourne; Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Murphy DA; Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne, Victoria, Australia., Hajkowicz K; Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Queensland, Australia; Centre for Clinical Research, University of Queensland, Brisbane, Australia., Wright EJ; Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Infectious Disease, Alfred Health, Monash University, Melbourne, Victoria, Australia; The Burnet Institute, Melbourne, Victoria, Australia.
Jazyk:	angličtina
Zdroj:	Public health research & practice [Public Health Res Pract] 2023 Sep 13; Vol. 33 (3). Date of Electronic Publication: 2023 Sep 13.
DOI:	10.17061/phrp3332328
Abstrakt:	The emergency phase of the coronavirus disease 2019 (COVID-19) pandemic is over. Still, the work goes on in understanding the SARS-CoV-2 virus and its evolution, infection impacts - acute and long term - as well as therapeutics and the lessons for preventing and responding to future pandemics. Research into the long-term post-infection effects and therapeutic interventions also expands as the post-infection period lengthens. We provide an overview of the leading edge of COVID-19 research across clinical, epidemiological and social domains. Competing Interests: CB declares honorarium from Novavax as part of the Australian Vaccine Advisory Group; acting as an expert witness on a range of legal cases relating to the pandemic and other epidemiological matters; and payment from Moderna for presenting on COVID-19 issues. BR is employed by the ASHM, which convened the Australasian COVID-19 Conference 2023. SM reports a grant from the Health Research Council of New Zealand for participation in ASCOT and REMAP-CAP trials for COVID-19 treatment; was a member of the Therapeutics Advisory Group to the New Zealand Ministry of Health and a member of the NZ national guidelines writing group for COVID-19. KH reports a grant and consulting fees/honorarium from Gilead Sciences and consulting fees and travel support from Moderna to attend meetings.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu